PharmaCyte Biotech, Inc. (PMCB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 04-30. Amounts in USD.

Revenue Annual

0 FY17: 0 FY18: 0 FY19: 0 FY20: 0 FY21: 0 FY22: 0 FY23: 0 FY24: 0 FY25: 0 FY26: 0 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Gross Profit Annual

0 35K 70K 105K FY11: 93.9K FY12: 47.2K FY13: 2.5K FY14: 0 FY15: 0 FY16: 0 FY11 FY12 FY13 FY14 FY15 FY16

Operating Income Annual

-9M -6M -3M 0 3M 6M 9M FY17: -4.4M FY18: -7M FY19: -4.1M FY20: -3.8M FY21: -3.6M FY22: -4.4M FY23: -6.5M FY24: -8.5M FY25: -4.4M FY26: -6.9M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Net Income Annual

-30M -15M 0 15M 30M 45M FY17: -4.4M FY18: -6.8M FY19: -4.1M FY20: -3.8M FY21: -3.6M FY22: -4.2M FY23: -4.3M FY24: 333.8K FY25: 30.7M FY26: -19.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Cost of Revenue Annual

0 15K 30K 45K FY11: 32.1K FY12: 19.4K FY13: 9.6K FY14: 0 FY15: 0 FY16: 0 FY11 FY12 FY13 FY14 FY15 FY16

Operating Cash Flow Annual

-6M -4M -2M 0 2M 4M 6M FY17: -3.3M FY18: -5.1M FY19: -2.9M FY20: -2.3M FY21: -3.3M FY22: -4.1M FY23: -3.8M FY24: -2.2M FY25: -3M FY26: -5.2M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

0 400M 800M 1.2B FY17: 845.3M FY18: 968.6M FY19: 1.1B FY20: 903.8K FY21: 1.4M FY22: 15.5M FY23: 19.5M FY24: 9.6M FY25: 7.3M FY26: 8.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '15: -0.04 Q2 '15: -0.04 Q3 '15: -0.04 Q4 '15: -0.02 Q1 '16: -0.02 Q2 '16: -0.01 Q3 '16: -0.01 Q4 '16: 0.00 Q1 '17: 0.00 Q2 '17: 0.00 Q3 '17: 0.00 Q4 '17: 0.00 Q1 '18: 0.00 Q2 '18: 0.00 Q3 '18: 0.00 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: -4.23 Q1 '21: -5.02 Q2 '21: -5.64 Q3 '21: -6.13 Q4 '21: -2.51 Q1 '22: -2.36 Q2 '22: -1.80 Q3 '22: -1.35 Q4 '23: -0.21 Q1 '24: -0.68 Q2 '24: -0.85 Q3 '25: 0.74 Q4 '25: 2.59 Q1 '26: -0.54 Q2 '26: -1.39 Q3 '26: -1.12 Q4 '26: -3.00 Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '25 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.